VWA5B2 Inhibitors refers to a specific class of chemical compounds that exert their pharmacological effects by targeting the VWA5B2 protein. The acronym VWA5B2 stands for von Willebrand factor A domain-containing 5B2, which is a protein encoded by the VWA5B2 gene. This protein is involved in various cellular processes and is typically associated with the regulation of molecular pathways related to cell adhesion and signal transduction. The inhibitors within this chemical class are designed to specifically interact with the VWA5B2 protein, modulating its activity and potentially disrupting the normal cellular functions it participates in.
VWA5B2 Inhibitors is intricately designed to achieve a high degree of selectivity for the VWA5B2 protein. Through precise molecular interactions, these inhibitors may interfere with the binding of VWA5B2 to its target molecules or disrupt its participation in crucial cellular processes. The development and study of VWA5B2 Inhibitors contribute to our understanding of the intricate molecular mechanisms underlying cellular function, offering insights into potential avenues for modulating these processes. Researchers delve into the structural characteristics of these inhibitors to refine their specificity and enhance their pharmacological properties, aiming to unravel the intricacies of VWA5B2-associated pathways for potential applications in various scientific fields.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $179.00 $307.00 $455.00 $924.00 $1689.00 | 7 | |
Inhibits myosin II, potentially altering cell adhesion and migration processes linked to VWA domains. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $100.00 $380.00 | 15 | |
A matrix metalloprotease inhibitor, possibly affecting extracellular matrix remodeling associated with VWA domains. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Broad-spectrum metalloprotease inhibitor, could influence extracellular matrix interactions. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $52.00 $87.00 | 7 | |
Inhibits metalloproteinases indirectly by chelating zinc ions, which are crucial for their activity. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Integrin inhibitor, may affect cell-matrix interactions involving VWA domain-containing proteins. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor, potentially affecting signaling cascades involved in cell adhesion and migration. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor, may disrupt signaling pathways linked to cellular processes involving VWA domains. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor, could influence cell matrix interactions and adhesion. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
ROCK inhibitor, potentially affecting cell morphology and adhesion associated with VWA domain proteins. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
Inhibits collagen type I synthesis, potentially influencing extracellular matrix composition. | ||||||